Nothing Special   »   [go: up one dir, main page]

MX2017009699A - Composicion de suspension oftalmica. - Google Patents

Composicion de suspension oftalmica.

Info

Publication number
MX2017009699A
MX2017009699A MX2017009699A MX2017009699A MX2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A
Authority
MX
Mexico
Prior art keywords
ophthalmic
suspension composition
ophthalmic suspension
âμm
suspension
Prior art date
Application number
MX2017009699A
Other languages
English (en)
Inventor
phillips Eric
J Coffey Martin
Shawer Mohannad
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55359733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2017009699A publication Critical patent/MX2017009699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una suspensión incluye un ingrediente activo oftálmico suspendido en un vehículo de formulación que incluye un agente de suspensión y un derivado de celulosa no iónico. El agente activo oftálmico está presente como partículas que tienen Dv90 <5 µm y Dv50 <1 µm. La suspensión se puede administrar a un paciente para tratar una afección inflamatoria oftálmica.
MX2017009699A 2015-01-26 2016-01-26 Composicion de suspension oftalmica. MX2017009699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562107696P 2015-01-26 2015-01-26
PCT/US2016/014872 WO2016123079A1 (en) 2015-01-26 2016-01-26 Ophthalmic suspension composition

Publications (1)

Publication Number Publication Date
MX2017009699A true MX2017009699A (es) 2017-10-23

Family

ID=55359733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009699A MX2017009699A (es) 2015-01-26 2016-01-26 Composicion de suspension oftalmica.

Country Status (14)

Country Link
US (3) US10596107B2 (es)
EP (5) EP4268850A1 (es)
JP (1) JP2018507252A (es)
KR (1) KR102538370B1 (es)
CN (1) CN107427464B (es)
AU (3) AU2016211745A1 (es)
BR (1) BR112017016016B1 (es)
CA (1) CA2975106A1 (es)
ES (4) ES2704125T3 (es)
HU (4) HUE048564T2 (es)
MX (1) MX2017009699A (es)
PL (4) PL3721868T3 (es)
PT (2) PT4082531T (es)
WO (1) WO2016123079A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4082531T (pt) 2015-01-26 2023-12-14 Bausch & Lomb Composição de suspensão oftálmica
US11103451B2 (en) 2015-10-16 2021-08-31 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
ES2972417T3 (es) 2016-05-18 2024-06-12 Sonikure Holdings Ltd Sistema de administración transescleral de fármacos mejorada por ultrasonidos
WO2019036483A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation AQUEOUS NEBULIZATION COMPOSITION
BR112021005097A2 (pt) * 2018-09-21 2021-06-08 Ps Therapy Ltd. lágrima artificial, lentes de contato e composições de veículos medicinais e métodos de uso dos mesmos
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2020165840A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
WO2021034850A1 (en) * 2019-08-18 2021-02-25 Iview Therapeutics, Inc. In-situ gel forming ophthalmic formulations containing difluprednate
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
DE3486448T2 (de) 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IE63392B1 (en) 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2134376C (en) 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
US5556848A (en) 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
PT2116227E (pt) 2003-06-13 2013-06-28 Novartis Ag Composições oftálmicas que contêm uma combinação sinérgica de dois polímeros
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20120028947A1 (en) 2005-11-14 2012-02-02 Erning Xia Ophthalmic Compositions
US20100234336A1 (en) 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
CN101966143A (zh) 2009-07-28 2011-02-09 胡容峰 加替沙星温度及pH敏感眼用凝胶的制备与应用
WO2011068872A2 (en) 2009-12-03 2011-06-09 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspension
AU2012312816A1 (en) * 2011-09-22 2014-04-24 Bausch & Lomb Incorporated Ophthalmic gel compositions
EP2844295A1 (en) 2012-05-03 2015-03-11 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
ES2727474T3 (es) 2012-05-08 2019-10-16 Nicox Ophthalmics Inc Nanocristales de propionato de fluticasona
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CA2867236C (en) * 2012-05-11 2017-02-28 Activus Pharma Co., Ltd. Organic compound nano-powder, method for producing the same and suspension
US20160051503A1 (en) 2012-08-31 2016-02-25 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
US20150190407A1 (en) 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
AU2015288644B2 (en) 2014-07-11 2017-12-14 Fujifilm Corporation Aqueous ophthalmic composition
NZ728136A (en) 2014-07-11 2017-10-27 Fujifilm Corp Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
PT4082531T (pt) 2015-01-26 2023-12-14 Bausch & Lomb Composição de suspensão oftálmica

Also Published As

Publication number Publication date
BR112017016016B1 (pt) 2023-12-19
AU2023248145A1 (en) 2023-11-02
EP4082531A1 (en) 2022-11-02
EP3470059A1 (en) 2019-04-17
BR112017016016A2 (pt) 2018-03-20
EP4082531B1 (en) 2023-10-11
ES2966595T3 (es) 2024-04-23
AU2016211745A1 (en) 2017-08-31
WO2016123079A1 (en) 2016-08-04
JP2018507252A (ja) 2018-03-15
EP3250185A1 (en) 2017-12-06
PL3470059T3 (pl) 2020-11-30
EP3721868B1 (en) 2022-06-01
PT4082531T (pt) 2023-12-14
US20230140895A1 (en) 2023-05-11
AU2021203027A1 (en) 2021-06-10
ES2704125T3 (es) 2019-03-14
US11534395B2 (en) 2022-12-27
HUE059639T2 (hu) 2022-12-28
KR102538370B1 (ko) 2023-06-01
AU2021203027B2 (en) 2023-07-13
PL4082531T3 (pl) 2024-04-08
EP4268850A1 (en) 2023-11-01
PL3250185T3 (pl) 2019-05-31
PL3721868T3 (pl) 2022-11-07
CN107427464B (zh) 2022-04-05
EP3250185B1 (en) 2018-12-05
ES2787039T3 (es) 2020-10-14
HUE066045T2 (hu) 2024-07-28
CA2975106A1 (en) 2016-08-04
ES2924645T3 (es) 2022-10-10
EP3721868A1 (en) 2020-10-14
HUE048564T2 (hu) 2020-08-28
US20200214977A1 (en) 2020-07-09
CN107427464A (zh) 2017-12-01
EP3470059B1 (en) 2020-04-01
HUE041945T2 (hu) 2019-06-28
PT3721868T (pt) 2022-08-12
KR20170105610A (ko) 2017-09-19
US10596107B2 (en) 2020-03-24
US20160213609A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
MX2017009699A (es) Composicion de suspension oftalmica.
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
EP4279064A3 (en) Drug delivery from hydrogels
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
MX2018005932A (es) Microparticulas aglomerantes para terapia medica.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
MX2017014340A (es) Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
BR112017016483A2 (pt) encapsulamento de agentes ativos de potência alta
MY183106A (en) Fine dry particulate retinoid active agent compostions and topical formulations including the same
MX2021004766A (es) Composiciones multifásicas.
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
NZ701665A (en) Trehalose-containing mammalian cell suspension for prevention of pulmonary embolism formation
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
EA201890703A1 (ru) Коллоидные частицы, предназначенные для применения в медицине
MX2018003799A (es) Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla.
TW201613596A (en) Ophthalmic suspension preparation
AR106690A1 (es) Método para administrar escualamina o una sal farmacéuticamente aceptable a la esclerótica posterior y a la coroides del ojo
HK1216233A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑